GOVX has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
GOVX has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Geovax Labs's Revenue per Share for the three months ended in Sep. 2024 was $0.44.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Revenue per Share growth rate.
During the past 13 years, the highest 3-Year average Revenue per Share Growth Rate of Geovax Labs was 253.00% per year. The lowest was -96.10% per year. And the median was -13.60% per year.
For the Biotechnology subindustry, Geovax Labs's 3-Year Revenue Growth Rate, along with its competitors' market caps and 3-Year Revenue Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, Geovax Labs's 3-Year Revenue Growth Rate distribution charts can be found below:
* The bar in red indicates where Geovax Labs's 3-Year Revenue Growth Rate falls into.
This is the 3-year average growth rate of Revenue per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Revenue per Share growth rate.
Geovax Labs (NAS:GOVX) 3-Year Revenue Growth Rate Explanation
Revenue per Share is the amount of Revenue per outstanding share of the company's stock.
Revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top. Revenue per share growth rate is used in calculating Predictability Rank, companies with more consistent revenue and earnings growth are ranked high with predictability.
Thank you for viewing the detailed overview of Geovax Labs's 3-Year Revenue Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.
David A Dodd | director | C/O SEROLOGICALS CORP, 5565 SPALDING DR, NORCROSS GA 30092 |
Mark Reynolds | officer: Chief Financial Officer | TWO BALA PLAZA, SUITE 300, PHILADELPHIA PA 19004 |
Mckee Kelly T. Jr. | officer: Chief Medical Officer | 233 VALLEY MEADOW DRIVE, CHAPEL HILL NC 27516 |
Jayne Morgan | director | 1900 LAKE PARK DRIVE, SUITE 380, SMYRNA GA 30080 |
Randal D Chase | director | 28 GEORGIA COURT, RICHMOND HILL A6 L4E ON7 |
Nicole Lemerond | director | 3 MURRAY HILL ROAD, SCARSDALE NY 10583 |
John W. Sharkey | officer: VP, Business Development | 16857 E. SAGUARO BLVD., FOUNTAIN HILLS AZ 85268 |
Dean G Kollintzas | director | 1256 BRIARCLIFF ROAD N.E., EMTECH BIO SUITE 500, ATLANTA GA 30306 |
Spencer John N Jr | director | 2859 PACES FERRY RD, STE 1000, ATLANTA GA 30339 |
Robert T Mcnally | director | |
Farshad Guirakhoo | officer: Sr VP, Research & Development | 39 CHESTNUT STREET, MELROSE MA 02176 |
Steven S. Antebi | director | 10550 FONTENELLE WAY, LOS ANGELES CA 90077 |
Harriet L Robinson | other: Chair, Scientific Adv Brd | 1256 BRIARCLIFF ROAD N.E., EMTECH BIO SUITE 500, ATLANTA GA 30306 |
Mark J Newman | officer: VP, Research & Development | 1900 LAKE PARK DR, SUITE 380, SMYRNA GA 30080 |
Peter M Tsolinas | director | 123 JOAN DRIVE, BARRINGTON IL 60010 |
From GuruFocus
By Marketwired • 12-09-2024
By GuruFocus Research • 03-03-2024
By GuruFocus Research • 03-03-2024
By Marketwired • 08-15-2024
By Marketwired • 09-03-2024
By GuruFocus News • 10-09-2024
By Marketwired • 08-20-2024
By Marketwired • 07-31-2024
By Marketwired • 07-31-2024
By Marketwired • 11-26-2024
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.